Stevanato Group's (STVN) "Outperform" Rating Reiterated at William Blair

Stevanato Group (NYSE:STVN - Get Free Report)'s stock had its "outperform" rating reissued by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued estimates for Stevanato Group's Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS and Q4 2026 earnings at $0.23 EPS.

Several other brokerages have also recently issued reports on STVN. Wolfe Research started coverage on shares of Stevanato Group in a research note on Friday, December 13th. They issued an "outperform" rating and a $28.00 price objective on the stock. UBS Group dropped their price target on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research note on Friday. Morgan Stanley restated an "equal weight" rating and issued a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Finally, Bank of America boosted their target price on Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of €27.75 ($30.16).

Stevanato Group Stock Performance

Shares of NYSE STVN traded down €1.40 ($1.52) during midday trading on Friday, reaching €21.20 ($23.04). 257,600 shares of the company were exchanged, compared to its average volume of 349,993. The stock has a market cap of $6.42 billion, a P/E ratio of 45.11, a PEG ratio of 7.18 and a beta of 0.60. Stevanato Group has a 1 year low of €16.56 ($18.00) and a 1 year high of €33.49 ($36.40). The stock has a fifty day simple moving average of €21.39 and a 200 day simple moving average of €20.59. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

Remove Ads

Stevanato Group (NYSE:STVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting analysts' consensus estimates of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to analysts' expectations of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. On average, research analysts forecast that Stevanato Group will post 0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stevanato Group

A number of hedge funds and other institutional investors have recently modified their holdings of STVN. Van Berkom & Associates Inc. acquired a new stake in shares of Stevanato Group in the 4th quarter worth approximately $39,000. Johnson Financial Group Inc. acquired a new stake in Stevanato Group in the fourth quarter valued at $41,000. Wells Fargo & Company MN increased its position in shares of Stevanato Group by 680.3% in the fourth quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock valued at $71,000 after buying an additional 2,830 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock valued at $123,000 after buying an additional 5,291 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Stevanato Group by 202.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company's stock worth $162,000 after buying an additional 4,965 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.